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Background. The activation of inﬂammatory cascades triggered by ischemic stroke may play a key role in the development of
infections. Methods. Patients admitted with ischemic stroke within 24 hours were prospectively enrolled. Biomarkers of infection
were measured on days 1, 3, and 5. The patients were continuously monitored for predeﬁned infections. Results. Patients with
infectionwereolder(OR1.06peryear,95%CI1.01–1.11)andhadahigherNationalInstituteofHealthStrokeScaleScore(NIHSS,
OR 1.21, 95% CI 1.10–1.34), localization in the insula, and higher stroke volumes on diﬀusion-weighted imaging. The maximum
temperature on days 1 and 3, leukocytes, interleukin-6, lipopolysaccharide-binding protein on days 1, 3, and 5, C-reactive protein
on days 3 and 5, and procalcitonin on day 5 were higher and HLA-DR-expression on monocytes on days 1, 3, and 5 lower in
patients with infection. Age and NIHSS predicted the development of infections. Infection was an independent predictor of poor
functional outcome. Conclusions. Severe stroke and increasing age were shown to be early predictors for infections after stroke.
1.Introduction
Infections complicating acute ischemic stroke contribute
to mortality and poor functional outcome after stroke in
most clinical studies [1–6]. Pneumonia occurs in 5–22%
and is the most common cause of death in stroke patients
[1–8]. The risk of infection is highest in the acute phase
after stroke [4] which may be attributed to stroke-induced
immunodepression syndrome (SIDS). SIDS is characterized
by loss of lymphocytes through apoptosis, shift of T-helper
cell 1 to 2 cytokine production, decreased monocyte count
and function, and interferon γ deﬁciency which begins a few
hours after ischemia and lasts for several weeks. These eﬀects
are associated with infection after stroke [9, 10]. Biomarkers
may facilitate an early diagnosis of infection in patients with
acute ischemic stroke [11].
In this study we attempted to deﬁne biomarkers of early
infection, identify early predictors of infection during the
hospital course after acute ischemic stroke and the impact
of infection on functional outcome after 3 months.
2.MaterialandMethods
2.1. Patient Population. Patients admitted to our stroke unit
during one year were enrolled in the study if they (1)
had symptoms and signs of an acute ischemic stroke, (2)
were treated within 24 hours after symptom onset, (3) had
a premorbid modiﬁed Rankin Scale score (mRS) of 0 to
1, and (4) gave informed consent. Patients were excluded
from the study if they (1) had an intracranial hemorrhage,
hypoglycemia, or other causes of a new focal deﬁcit, (2)2 Stroke Research and Treatment
had contraindications against magnetic resonance imaging
(MRI), (3) were taking antibiotics, (4) were immunocom-
promised by chemotherapy or acquired immunodeﬁciency
syndrome, (5) had severe comorbidities, or (6) could not
participate in the follow-up examination. The comprehen-
sive stroke unit encompasses 8 monitored beds for stroke
patients and 4 monitored beds with capacity for mechanical
ventilation (neurointensive care unit). Patient recruitment
was performed prospectively. The study was approved by
the local ethics committee. Written informed consent was
obtained from all patients (or their legal guardian) prior to
participating in the study.
2.2. Clinical Management and Data. The patients were
treated according to the guidelines of management of acute
ischemic stroke [12, 13]. The patients were screened on
admission (day 1); demographic data, medical history
including the presence of an infection in the last two
weeks and medications prior to admission (speciﬁcally
antibiotics) and risk factors, and vital signs were obtained.
The temperature was measured continuously utilizing the
temperature probe of the urinary catheter if placed or an
axillary temperature probe. The maximum daily temper-
ature was charted on days 1 and 3. Clinical examination
encompassed a general evaluation, the National Institute of
Health Stroke Scale (NIHSS), and mRS [14]. The patients
received an electrocardiogram, a focused MRI (diﬀusion-
weighted imaging = DWI and ﬂuid attenuated inversion
recovery imaging = FLAIR), and a chest radiograph on day
1. Laboratory markers on admission included a complete
b l o o dc o u n tw i t hd i ﬀerential, renal, and liver function tests,
cardiac enzymes, and a urine analysis. The inﬂammatory
markers,whitebloodcells(WBCs),C-reactiveprotein(CRP)
[15, 16], procalcitonin (PCT), interleukin-6 (IL-6) [16–20],
HLA-DR-expression on monocytes (HLADRM) [16, 19, 21],
and lipopolysaccharide-binding protein (LBP) [22], were
collected on days 1, 3, and 5 along with the mean body
temperature (measured every 1–4 hours). The biomarkers
were measured by chemical luminescence immunoassay
(Immulite DPC Biermann, Siemens Diagnostics, Germany)
(IL-6, LBP), automated immunoﬂuorescent assay (Kryptor
Brahms Diagnostica, Berlin, Germany), immunoturbidime-
try (AU 600 Olympus, Dallas, TX, USA) (CRP), electrical
impedance or ﬂow cytometry (SE 9000 Sysmex, Digitana,
Horgen, Switzerland) (WBC), and ﬂow cytometry (EPICS
XL, Beckman Coulter, Fullerton, CA, USA) (HLADRM).
Another focused MRI (DWI and FLAIR) was performed on
days 5–7. The infarction and edema volumes were calculated
on DWI (day 1) and FLAIR (days 5–7) using the planimetry
method [23]. All infections and procedures, presence of
dysphagia from admission through day 5, duration of
hospital stay, the localization, and ﬁnal etiology of the
ischemic stroke according to the TOAST criteria [24]w e r e
recorded. Hospital procedures included the placement of
urinary catheters in patients with urinary incontinence,
requiringclosemonitoringoftheﬂuidbalanceormechanical
ventilation; central lines in patients with impaired peripheral
venous access, with sepsis or other causes for hemodynamic
instability, requiring mechanical ventilation or vasopressors;
mechanical ventilation for respiratory failure or airway
protection.
2.3. Outcome Measures. The patients were screened for
predeﬁned infections until discharge: systemic inﬂammatory
response (SIRS: two of the following criteria: tempera-
ture >38◦C, <36◦C; heart rate >90/min; respiratory rate
>20/min, paCO2 <32mmHg, or mechanical ventilation;
WBC >12Gpt/L, <4Gpt/L or 10% blasts), sepsis (SIRS
resulting from a presumed or known site of infection),
upper respiratory tract infection (2 of the following criteria:
purulent sputum, fever >38◦C; WBC >12Gpt/L, <4Gpt/L
or 10% blasts, no rales or rhonchi on auscultation and/or
dullness on percussion, no requirement of supplemental
oxygen), and pneumonia (purulent sputum, fever >38◦C;
WBC >12Gpt/L, <4Gpt/L or 10% blasts, new inﬁltrate on
chest radiograph, requirement for supplemental oxygen),
urinary tract infection (urinary analysis with evidence
of WBC and nitrite, increased CRP or WBC >12Gpt/L,
<4Gpt/L or 10% blasts and/or clinical signs such as frequent
urination, dysuria, ﬂank pain, and/or positive urine culture),
gastritis (conﬁrmation by endoscopy, test for Helicobacter
pylori). Pneumonia, SIRS, and sepsis were considered serious
infections (requiring prolongation of hospitalization, caus-
ing neurological deterioration, and monitoring in the neuro-
intensive care unit); upper respiratory, gastritis, and urinary
tract infections (UTI) were deﬁned as nonserious (no
impact on neurological function, not requiring continuous
monitoring). The infections were treated according to the
national guidelines [25]. Patients with UTI according to the
laboratory criteria not accompanied by fever and clinical
symptoms of UTI received oral or intravenous ﬂuids along
with vitamin C (hospital standard).
Functionaloutcomewasassessedat90±14daysusingthe
mRS (0 = full recovery, 6 = death) [14]; poor outcome was
deﬁned as death, moderate or severe disability (mRS score 3
to 6).
2.4. Statistical Analysis. Data analyses were performed with
commercially available statistical software (17.0, SPSS,
C h i c a g o ,I L ,U S A ) .T h ed a t aw e r ec o m p l e t ef o ra l lo u t c o m e
variables. Univariate associations between demographic,
clinical, radiological variables, inﬂammatory markers, and
poor outcome were tested with Chi-square or Fisher’s exact
test for categorical variables, two-tailed t-test for normally
distributed continuous variables, and Mann-Whitney U test
for nonnormally distributed continuous variables. Among
similar clinical variables that were intercorrelated (involve-
ment of the anterior or entire insula; stroke volume on DWI
orFLAIR),onlythevariablewiththehighestoddsratio(OR)
and smallest P value in the binary logistic regression analysis
was used as a candidate variable in the ﬁnal multivariate
model. Signiﬁcant predictors of infection, serious infec-
tion, and poor outcome among the demographic, clinical,
radiological variables, biochemical markers of day 1 were
identiﬁed in a backward stepwise logistic regression model.
P values <.05, was considered signiﬁcant. We also tested forStroke Research and Treatment 3
Table 1: Univariate associations of demographic, baseline, vital signs, hospital complications, and procedures with the development of an
infection and serious infection during the hospital stay.
No infection N = 55 Infection N = 39 P Serious infection N = 19 P∗
Demographics, clinical variables on admission
Age (years) 69.2 ±1.67 5 .5 ±8.9 .006 74.6 ±2.2N S
Male sex 28 15 NS 8 NS
Time symptom onset to admission
(hours)
5.2 ±0.73 .8 ±0.7N S 2 .8 ±1.2N S
History of diabetes mellitus 18 17 NS 9 NS
History of hypertension 44 37 NS 18 NS
History of metabolic syndrome 15 14 NS 5 NS
History of coronary artery disease 24 20 NS 11 NS
History of stroke 95 N S 3 N S
Admission NIHSS 8.3 ±0.61 3 .3 ±0.9 <.0001 14.8 ±1.3 <.0001
Thrombolysis (IV and/or IA) 18 15 NS 10 NS
Systolic blood pressure on
admission (mmHg)
161.0 ±4.1 170.6 ±5.0 NS 171.6 ±7.0N S
Diastolic blood pressure on
admission (mmHg)
85.2 ±2.58 4 .9 ±3.2N S 8 4 .0 ±4.3N S
Heart rate on admission (bpm) 81.6 ±2.08 2 .0 ±2.5N S 8 3 .50 ±3.6N S
Oxygen saturation on admission
(%)
95.6 ±0.49 5 .3 ±0.3N S 9 4 .7 ±0.6N S
Hospital complications and procedures
Dysphagia 82 3 <.0001 16 <.0001
Central line 11 4 <.0001 13 <.0001
Urinary catheter 16 38 <.0001 19 <.0001
Mechanical ventilation 11 1 <.0001 10 <.0001
Length of hospital stay (days) 9.9 ±0.71 7 .3 ±1.2 <.0001 20.7 ±2.1 <.0001
Radiological variables
DWI volume day 1 (cm3) 11.3 ±3.54 5 .6 ±11.9 .002 58.0 ±20.2 .001
FLAIR volume day 5–7 (cm3) 15.8 ±4.27 5 .6 ±17.8 <.0001 105.3 ±32.1 <.0001
Location of stroke
Anterior insula included 0 3 .037 1 NS
Posterior insula included 92 N S 1 N S
Entire insula included 31 3 <. 0001 8 .001
MCA territory 40 29 NS 15 NS
ACA territory 12 N S 1 N S
PCA territory 19 7 NS 3 NS
Brain stem 44 N S 2 N S
Cerebellum 51 N S 1 N S
Right sided stroke 25 16 NS 9 NS
Left sided stroke 24 19 NS 8 NS
Bilateral stroke 64 N S 2 N S4 Stroke Research and Treatment
Table 1: Continued.
No infection N = 55 Infection N = 39 P Serious infection N = 19 P∗
Outcome
mRS at 3 months
0 30 <.0001 0 <.0001
1 11 1 0
2 23 4 1
3 15 11 2
4 21 4 1 0
5 12 2
6 07 4
Data are shown as number for dichotomized variables mean ± standard error of the mean (SEM) for normally distributed continuous variables, or median
(range) for abnormally distributed continuous variables. ∗P value for analysis of serious infection versus no infection.
NIHSS: National Institute of Health Stroke Scale; IV: intravenous; IA: intra-arterial; DWI: diﬀusion weighted imaging; FLAIR: ﬂuid attenuated inversion
recovery imaging; MCA: middle cerebral artery; ACA: anterior cerebral artery; PCA: posterior cerebral artery; mRS: modiﬁed Rankin scale.
interactions between all independent predictors of outcome
in the ﬁnal model.
In a second step, age, NIHSS, and markers of infection
were dichotomized at the threshold producing the largest
area under the curve produced by a receiver operating
characteristic (ROC) curve and were entered into a model to
calculate the likelihood of infection or serious infection after
acute ischemic stroke in order to identify highly predictive
threshold values.
3. Results
Ninety-six patients were enrolled in the study from Novem-
ber 2007 through October 2008; 2 patients were excluded
from the analysis for current antibiotic treatment upon
stroke symptom onset. The mean age was 71.8 ± 1.2y e a r s ,
and 46% of the patients were male. The baseline NIHSS was
9.5 (0–24). The cause of stroke was atherothrombosis in 35
(37%) of patients, cardioembolism in 21 (22%) of patients,
lacunar infarction in 22 (23%), and cryptogenic in 15 (16%)
of patients according to the TOAST criteria.
The rate of infection in all patients was 42% (39/94
patients), and infection of those 20 patients (51%) had
a nonserious and 19 (49%) a serious infection (Table 1).
Pneumonia was diagnosed in 17 (18%), catheter-related
sepsis in 2 (2%), urinary tract infections in 27 (29%), upper
respiratory tract infection in 1 (1%), and gastritis in 5
patients (5%). 10 patients (11%) developed more than one
infection during the hospital stay, and 29 patients (31%)
received antibiotics.
Several demographic, clinical, and radiological variables
on admission and during the hospital stay as well as markers
of infection on days 1, 3, 5 were associated with a develop-
ment of an infection or serious infection during the hospital
stay (Tables 1 and 2). Among them, inclusion of the insular
region, only present in large territorial middle cerebral artery
(MCA) infarction, was signiﬁcantly linked with infection
after ischemic stroke. Backward stepwise logistic regression
(P<. 05) identiﬁed higher age and NIHSS on admission
as the earliest independent predictors of infection (Table 3).
None of the laboratory markers of infection remained
signiﬁcantinthemultivariatemodel.Maximumtemperature
as part of the deﬁnitions of infections was removed from the
ﬁnalmodel.HigherNIHSSwasanindependentpredictorfor
development of a serious infection after stroke (Table 3).
To identify a threshold for the development of infection
from a combination of signiﬁcant admission predictors
of infection and serious infection, the admission predic-
tors were dichotomized according to their sensitivity and
speciﬁcity in the ROC curve (infection: NIHSS ≥ 8.5,
age ≥ 72 years, LBP ≥ 17.5mcg/mL, WBC ≥ 7.55Gpt/L,
serious infection: NIHSS ≥ 8.5, age ≥ 69.5 years, LBP ≥
18.5mcg/mL). However, their sensitivities and speciﬁcities
ranged between 50% and 70%. Therefore, a threshold for the
development of an infection or serious infection with a high
likelihood when the patient presents with a combination of
certain factors and laboratory markers could not be found.
However, PCT ≥ 0.07ng/mL, IL-6 ≥ 6.9pg/mL, and WBC
≥ 7.45Gpt/L on day 5 were signiﬁcantly associated with
the presence of a serious infection (PCT and IL-6 with a
sensitivity and speciﬁcity >90%, WBC with a sensitivity
>80%, speciﬁcity >70%, Table 4).
Advanced age, higher NIHSS on admission, and larger
ﬁnal stroke volume (FLAIR day 5–7) as well as infection
were independent predictors of moderate to severe disability
and mortality at 3 months after stroke in the multivariate
model (P<. 05). As NIHSS and ﬁnal stroke volume were
intercorrelated, FLAIR stroke volume was removed from the
ﬁnal model as NIHSS is easier and more rapidly obtained
on admission (Table 5). Of those predictors, the presence of
infection had the highest likelihood ratio (OR 6.34, 95% CI
1.81–22.22).
4. Discussion
Our study demonstrates the higher likelihood of infection
after ischemic infarctions for older patients with a more
severe stroke (higher NIHSS on admission). Patients with a
severe stroke are more prone to a serious infection during
the hospital stay. Infection had a detrimental impact on 3Stroke Research and Treatment 5
Table 2: Univariate associations of laboratory markers of infection with the development of an infection and serious infection during the
hospital stay.
No infection N = 55 Infection N = 39 P Serious infection N = 19 P∗ Normal Range
Markers of Infection
Mean temperature day 1 (◦C) 36.7 ±0.13 7 .4 ±0.1 <.0001 37.4 ±0.2 .001
Mean temperature day 3 (◦C) 36.9 ±0.13 7 .7 ±0.1 <.0001 37.9 ±0.1 <.0001
Procalcitonin day 1 (ng/mL) 0.05 ±0.01 0.29 ±0.23 NS 0.53 ±0.01 NS <0.5
Procalcitonin day 3 (ng/mL) 0.05 ±0.01 0.34 ±0.24 NS 0.63 ±0.49 .04 <0.5
Procalcitonin day 5 (ng/mL) 0.05 ±0.01 0.20 ±0.05 .002 0.35 ±0.10 <.0001 <0.5
Interleukin-6 day 1 (pg/mL) 7.35 ±1.81 7 .0 ±4.15 .019 21.6 ±7.5 .009 <6.0
Interleukin-6 day 3 (pg/mL) 9.0 ±1.52 4 .2 ±4.0 <.0001 36.25 ±6.8 <.0001 <6.0
Interleukin-6 day 5 (pg/mL) 9.0 ±1.55 37.4 ±11.3 .004 64.6 ±21.5 <.0001 <6.0
Lipopolysaccaride-binding
protein day 1 (mcg/mL)
19.0 ±1.62 6 .6 ±2.8 .014 29.3 ±4.5 .008 <8.4
Lipopolysaccaride-binding
protein day 3 (mcg/mL)
25.0 ±2.14 4 .7 ±6.1 .001 54.3 ±10.9 <.0001 <8.4
Lipopolysaccaride-binding
protein day 5 (mcg/mL)
23.4 ±2.15 0 .9 ±6.0 <.0001 66.5 ±10.9 <.0001 <8.4
C-reactive protein day 1 (mg/L) 10.2 ±2.01 9 .2 ±5.2N S 2 2 .8 ±7.1 .022 0–5.0
C-reactive protein day 3 (mg/L) 12.2 ±2.14 6 .7 ±9.45 <.0001 58.3 ±10.2 <.0001 0–5.0
C-reactive protein day 5 (mg/L) 10.0 ±1.47 8 .9 ±14.0 <.0001 113.7 ±24.9 <.0001 0–5.0
White blood cells day 1 (Gpt/L) 8.35 ±0.41 0 .3 ±0.5 .006 11.7 ±0.8 <.0001 4.0–11.0
White blood cells day 3 (Gpt/L) 8.3 ±0.81 1 .9 ±1.7 .034 11.3 ±0.8 .034 4.0–11.0
White blood cells day 5 (Gpt/L) 7.4 ±0.69 .6 ±0.5 .01 10.7 ±0.8 .006 4.0–11.0
Monozyte HLA-DR expression
day 1 (%)
96.0 ±0.79 2 .9 ±1.5 .039 92.1 ±2.4 .034 >30
Monozyte HLA-DR expression
day 3 (%)
95.1 ±1.28 8 .1 ±2.1 .002 89.1 ±2.0 .011 >30
Monozyte HLA-DR expression
day 5 (%)
94.2 ±1.38 8 .5 ±2.0 .014 85.6 ±3.1 .004 >30
Data are shown as number for dichotomized variables mean ± standard error of the mean (SEM) for normally distributed continuous variables, or median
(range) for abnormally distributed continuous variables. ∗P value for analysis of serious infection versus no infection.
Table 3: Independent day 1 predictors of infection and severe
infection.
OR (95% CI) P
Independent day 1 predictors of infection (N = 94)
Age (years) 1.06 (1.01–1.11) .020
NIHSS 1.21 (1.10–1.34) <.0001
Independent day 1 predictors of serious infection
(versus no infection, N = 74)
NIHSS 1.28 (1.23–1.46) <.0001
C-reactive protein (mg/L) 1.03 (1.0–1.06) .053
Binary logistic regression was used to calculate P values and adjusted odds
ratios (with 95% conﬁdence intervals).
NIHSS: National Institute of Health Stroke Scale.
months outcome after stroke. Aside from the randomized,
double blind, placebo-controlled trials of prevention of
infection after stroke with prophylactic antibiotic therapy
[26–29] and case control studies [15, 16, 21], this is the
ﬁrst clinical study to prospectively investigate predeﬁned
Table 4: Signiﬁcant associations of day 5 markers of infection with
serious infection.
Day 5 markers of infection OR (95% CI) P
Procalcitonin day 5 ≥
0.07ng/mL
51.2 (4.1–642.0) .002
Interleukin-6 day 5 ≥
6.9pg/mL
33.6 (2.1–547.0) .014
White blood cells day 5 ≥
7.45Gpt/L
24.7 (1.8–346.0) .017
Binary logistic regression was used to calculate P values and adjusted
odds ratios (with 95% conﬁdence intervals). The reference thresholds for
dichotomization of the inﬂammatory markers were selected based on a
receiveroperatingcharacteristiccurvetoidentifyalevelthatmostaccurately
distinguished presence and absence of infection or severe infection.
biomarkers and predictors of infection by means of sched-
uled blood collections for 6 laboratory infection markers,
neuroimaging, and daily screening for the presence of an
infection, to diﬀerentiate between nonserious and serious
infection, and with the intention to identify a threshold6 Stroke Research and Treatment
Table 5: Multivariate predictors of poor outcome (mRS 3–6) at 90
days.
mRS 0–2 mRS 3–6 OR (95% CI) P
N = 42 N = 52
Age (years) 66.7 ±1.77 5 .9 ±1.3 1.10 (1.03–1.17) .003
NIHSS 8.81 ±3.74 66.77 ±13.82 1.26 (1.09–1.46) .001
Infection 5 34 6.34 (1.81–22.22) .004
Data are shown as number for dichotomized variables, mean ± standard
error of the mean (SEM) for normally distributed continuous variables or
median (range) for abnormally distributed continuous variables. Binary
logistic regression was used to calculate P values and adjusted odds ratios
(with 95% conﬁdence intervals) for the multivariate model.
NIHSS: National Institute of Health Stroke Scale; mRS: modiﬁed Rankin
scale.
using a combination of variables associated with infection
to reliably predict the occurrence of an infection during
the hospital stay after stroke in combination with long-term
functional outcome.
SIDS is characterized by reduced CD3+ T cell, CD4+ and
CD8+ T helper cell counts [16, 17, 19], decreased interferon
γ production [16, 17], lymphopenia [18, 19], shift of T-
helper 1 to T helper 2 cells [18], leukocyte depression [30]
orelevation[15,16,19,20],raisedneutrophilcounts[16,20,
21],decreasedB-andT-cellcounts,increasedtumornecrosis
factor (TNF) α [16, 30], interleukin (IL)-5 [16], IL-6 [16–
20]a n dI L - 1 0l e v e l s[ 20, 30, 31], increased CRP levels [15,
16], decreased basophil and natural killer cell counts [21],
increased monocyte counts [16, 20, 21, 31], deactivation
of monocytes [18], and decreased HLA-DR density on
monocytes [16, 19, 21] in human or animal studies. In our
study population mean temperature, IL-6, LBP, and WBC on
day 1 were signiﬁcantly higher and HLADRM signiﬁcantly
reduced in patients who developed an infection, just as in
previous reports [16, 17, 19, 21]. Additionally, CRP was also
elevated on day 1 in patients who got a serious infection after
stroke [15, 16, 32]. None of these markers of infections or
PCT [16] proved sensitive enough on the day of symptom
onset to reliably predict the development of an infection
after stroke nor could a threshold for a combination of age,
NIHSS, temperature, and laboratory markers on day 1 be
identiﬁed. Another explanation may be that SIDS is still in
the process of development at this early time point with
diﬀerent biomarkers following diﬀerent time courses after
the stress response of the hypothalamic-pituitary-adrenal
axis [9, 10]. In the patients who encountered an infection,
the biomarkers seem to react by day 5 described by PCT
≥ 0.07ng/mL, IL-6 ≥ 6.9pg/mL, or WBC ≥ 7.45Gpt/L.
However, most of the infections are diagnosed in the acute
phase after stroke [4]. The role of insular cortex in SIDS
remains unclear. A trend to a higher occurrence of infection
after stroke with involvement of the insular cortex could
not be conﬁrmed in our multivariate model. Stroke severity,
for example, higher NIHSS, may be more important for the
development of infections; the insular cortex was involved in
larger MCA territory infarctions exclusively. Cortical infarcts
in the MCA territory were more frequent in patients with
infections after ischemic stroke in a case control study [15].
The impact of age and stroke severity on the likelihood
of infections after acute ischemic stroke was also seen in case
control studies as a correlation of infarct size [21, 30], worse
Scandinavian Stroke Scale on admission [15]o rd a y4[ 32],
or higher admission NIHSS [16, 20, 31] with the presence of
SIDS or infection.
The infection rate in our patient population amounted
to 42%. The frequency of infection was higher than reported
in other ischemic stroke populations [1–8, 33, 34]. However,
baseline NIHSS was higher 9.5 (0–24) in our stroke patients,
and the patients were prospectively screened, whereas most
of the study reports on infection after ischemic stroke are
retrospective. The rate of pneumonia was 18%, comparable
to other reports [1–8, 34–37]. Since all patients were treated
in a certiﬁed stroke and neurointensive care unit, measures
to prevent aspiration and ventilator-associated pneumonia
in stroke patients might have kept the rate of pneumonia low
while the overall rate of infection was high. The detrimental
impact of infection on functional outcome at 3 months after
stroke was conﬁrmed in our dataset [1–6, 34].
The relationship of infection risk and more severe
ischemic infarctions deﬁned by higher NIHSS on admission
or greater infarct volumes on neuroimaging seen in our
patient population has been established [20, 21, 30, 31].
Several randomized trials demonstrated a reduction of infec-
tion rate in stroke patients by prophylactic administration
of antibiotics but failed to show an impact on long-term
functionaloutcome[26–29].Twoofthefourstudiesenrolled
patients with higher NIHSS scores (>11) or who were
bedridden on admission [26, 27]. Prophylaxis of infection
with antibiotics in stroke patients is not recommended based
on the results of those four studies, but the eﬀect of close
monitoring for infection and early initiation of antibiotics
in older patients with severe ischemic stroke on clinical
outcome should be investigated.
A number of limitations of our study should be men-
tioned:apatientsamplesizeof94mayhavebeentoosmallto
identifyreliablethresholdsofbiomarkersforinfection.There
is a potential for referral bias in the overall patient proﬁles.
Two patients presented with an infection on admission along
with an acute ischemic stroke and were included in the study.
The multivariate models may have lacked statistical power
and validity underestimating possible eﬀects of biomarkers
and other potential predictors. The diagnosis of an infection
was not time-locked in the dataset, therefore, no statement
about the time course of markers of infection in relation
to the occurrence of the infection can be made. While the
biomarkers chosen to predict infection early are sensitive in
the setting of infection or inﬂammation, they may not be
speciﬁc for infection and/or immunodepression after acute
ischemic stroke and have diﬀerent time courses. Quantitative
analysis of HLADRM was not available.
In summary, patients with more severe ischemic stroke
and older age are more susceptible to the development of
an infection during the hospital course. The biomarkers
of infection studied may not be sensitive or speciﬁc to
predict the occurrence of an infection on the day of stroke
symptom onset and should not warrant the prophylactic use
of antibiotics. Future trials of infection prevention and earlyStroke Research and Treatment 7
initiation of treatment should include a careful selection of
the study population based on stroke severity and age.
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